Risk-Reducing Options for Women with a Hereditary Breast Cancer Predisposition

被引:16
作者
Jatoi, Ismail [1 ]
机构
[1] Univ Texas Hlth Sci Ctr San Antonio, Div Surg Oncol & Endocrine Surg, San Antonio, TX 78229 USA
关键词
Hereditary predisposition; breast cancer; risk-reducing options;
D O I
10.5152/ejbh.2018.4324
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Genetic testing is now widely utilized to identify women with a hereditary predisposition for breast cancer. Women who carry mutations that increase breast cancer risk may consider three options to reduce risk: screening, chemoprevention, and prophylactic surgery. Yet, no randomized trials have specifically assessed the efficacy of these options in mutation carriers. In many developed countries, mammography is regarded as the optimal means of screening for breast cancer in the general population. However, breast MRI is a more sensitive screening tool, and for mutation carriers, any breast cancer screening strategy should incorporate screening with MRI. In randomized trials of women at high risk for developing breast cancer, chemoprevention reduces that risk, but it has not been shown to reduce mortality. Finally, observational studies suggest that, in mutation carriers, prophylactic surgery may reduce the risk of developing breast cancer by 90-95%. There are several prophylactic mastectomy procedures to choose from, and these are generally done in conjunction with breast reconstruction. In this article, we discuss management of women who carry mutations that have been associated with an increased breast cancer risk. Mutation carriers should be informed of the potential risks and benefits of the three available options to reduce breast cancer risk.
引用
收藏
页码:189 / 193
页数:5
相关论文
共 42 条
  • [1] Assessing Women at High Risk of Breast Cancer: A Review of Risk Assessment Models
    Amir, Eitan
    Freedman, Orit C.
    Seruga, Bostjan
    Evans, D. Gareth
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2010, 102 (10): : 680 - 691
  • [2] Antoniou AC, 2014, NEW ENGL J MED, V371, P497, DOI [10.1056/NEJMc1410673, 10.1056/NEJMoa1400382]
  • [3] Risk-reducing mastectomy for the prevention of primary breast cancer
    Carbine, Nora E.
    Lostumbo, Liz
    Wallace, Judi
    Ko, Henry
    [J]. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2018, (04):
  • [4] Casaubon JT, 2018, BRCA 1 2 STATPEARLS
  • [5] Preventive therapy for cancer
    Cuzick, Jack
    [J]. LANCET ONCOLOGY, 2017, 18 (08) : E472 - E482
  • [6] Diagnostic and therapeutic ionizing radiation and the risk of a first and second primary breast cancer, with special attention for BRCA1 and BRCA2 mutation carriers: A critical review of the literature
    Drooger, Jan C.
    Hooning, Maartje J.
    Seynaeve, Caroline M.
    Baaijens, Margreet H. A.
    Obdeijn, Inge Marie
    Sleijfer, Stefan
    Jager, Agnes
    [J]. CANCER TREATMENT REVIEWS, 2015, 41 (02) : 187 - 196
  • [7] The Angelina Jolie effect: how high celebrity profile can have a major impact on provision of cancer related services
    Evans, D. Gareth R.
    Barwell, Julian
    Eccles, Diana M.
    Collins, Amanda
    Izatt, Louise
    Jacobs, Chris
    Donaldson, Alan
    Brady, Angela F.
    Cuthbert, Andrew
    Harrison, Rachel
    Thomas, Sue
    Howell, Anthony
    Miedzybrodzka, Zosia
    Murray, Alex
    [J]. BREAST CANCER RESEARCH, 2014, 16 (05):
  • [8] Population-based screening for breast and ovarian cancer risk due to BRCA1 and BRCA2
    Gabai-Kapara, Efrat
    Lahad, Amnon
    Kaufman, Bella
    Friedman, Eitan
    Segev, Shlomo
    Renbaum, Paul
    Beeri, Rachel
    Gal, Moran
    Grinshpun-Cohen, Julia
    Djemal, Karen
    Mandell, Jessica B.
    Lee, Ming K.
    Beller, Uziel
    Catane, Raphael
    King, Mary-Claire
    Levy-Lahad, Ephrat
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2014, 111 (39) : 14205 - 14210
  • [9] Gabriel EM, 2012, EXPERT REV ANTICANC, V12, P223, DOI [10.1586/era.11.206, 10.1586/ERA.11.206]
  • [10] The Role of Risk-Reducing Surgery in Hereditary Breast and Ovarian Cancer
    Hartmann, Lynn C.
    Lindor, Noralane M.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2016, 374 (05) : 454 - 468